Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

2016182 citationsJournal Articlegreen Open Access

Authors

Jozef Bartúnek · Onze Lieve Vrouwziekenhuis Hospital

André Terzic · Mayo Clinic

Beth A. Davison · Momentum Research

Gerasimos Filippatos · National and Kapodistrian University of Athens

S. Radovanović · University Hospital Medical Center Bezanijska kosa

Branko Beleslin · University of Belgrade

Béla Merkely

Abstract

The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Topics & Keywords

Mesenchymal stem cell research Tissue Engineering and Regenerative Medicine Cardiac Structural Anomalies and Repair

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 38, Issue 9, pp. ehw543-ehw543

DOI: 10.1093/eurheartj/ehw543

Field-Weighted Citation Impact: 16.74